Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company developing novel serotonergic agonists, issued a correction to its April 28, 2026 release regarding its partnership with TARA Mind. The correction removes references to Veterans Exploring Treatment Solutions from earlier paragraphs while reaffirming the collaboration’s alignment with a recent executive order aimed at advancing mental health treatments and clinical research participation.
The partnership is designed to support Phase 3 recruitment for Helus Pharma’s HLP003 program in major depressive disorder and expand outreach in veteran communities. HLP003, a proprietary novel serotonergic agonist (NSA), is currently in Phase 3 clinical development for the adjunctive treatment of major depressive disorder and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. The company’s NSAs are synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity, addressing the large unmet need for people suffering from depression, anxiety, and other mental health conditions.
Helus Pharma, the commercial operating name of Cybin Inc., founded in 2019, aims to improve the treatment landscape through NSAs that provide durable improvements in mental health. In addition to HLP003, the company is developing HLP004, a proprietary NSA in Phase 2 for generalized anxiety disorder, and has an extensive research portfolio of investigational NSAs. The company operates in Canada, the United States, the United Kingdom, and Ireland.
This correction is significant for investors and industry observers as it clarifies the scope of the partnership and underscores the company’s commitment to transparency. The reaffirmation of alignment with the executive order suggests that Helus Pharma’s initiatives may benefit from increased government support for mental health treatments. For leaders in business and technology, this news highlights the growing intersection of pharmaceutical innovation and policy, particularly in the mental health space. The executive order could accelerate clinical research participation and potentially streamline regulatory pathways for novel therapies like HLP003.
The correction also emphasizes the importance of accurate communication in clinical-stage companies, especially those with high-profile partnerships. Investors should monitor how this partnership impacts recruitment for the Phase 3 trial and whether the executive order leads to faster approvals or expanded access to treatments. For the broader industry, this development signals a continued focus on psychedelic-inspired therapies and their potential to address treatment-resistant conditions.
For more details, the full press release can be viewed at https://ibn.fm/re8HL. Latest news and updates relating to HELP are available in the company’s newsroom at https://ibn.fm/HELP.
